10.6亿与7亿美元!先声药业与荃信生物同日“借船出海”

药财社
Dec 22, 2025

▲关注药财社聚焦医药界▲今日(12月22日),中国创新药“出海”上演罕见“双响炮”:荃信生物与先声药业同日宣布,将核心创新药物授权给跨国伙伴,两笔License-out(对外授权)潜在总额最高达17.6亿美元,标志着中国原创分子在哮喘、特应性皮炎和实体瘤等重大疾病领域,正以“技术输出方”的身份参与全球分工。第一笔交易来自荃信生物。其长效抗TSLP(胸腺基质淋巴细胞生成素)/IL-13(白介素-13...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10